Compare Nike Inc (NKE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs TG Therapeutics Inc — how do they compare? Nike Inc trades at $37.44 (market cap $56.52B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: Nike Inc is far larger — about 6.6× TG Therapeutics Inc's market cap, and Nike Inc pays a 4.3% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| NKE | TGTX | |
|---|---|---|
Market Cap | $56.52B | $8.53B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $74.57 | $59.06 |
52-Week Low | $37.35 | $26.94 |
Enterprise Value | $58.53B | $8.74B |
Dividend Yield | 4.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $37.35, down 2.73% amid bearish technical signals and recent earnings volatility. The stock shows strong profitability metrics with 42.91% gross margins and 22.14% ROE, but faces revenue pressure with FY2025 sales declining to $46.31B. Analyst consensus remains positive with a $49.81 price target, though technical indicators signal caution with 17 sell signals versus 3 buy signals.
Nike's investment case balances strong brand equity and recent earnings beats against China market challenges and inventory pressures. The stock offers 33% upside to consensus targets but requires successful execution of the 'Win Now' turnaround strategy to overcome near-term headwinds in key markets.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
